Cue Biopharma (CUE) Debt to Equity (2022 - 2025)
Cue Biopharma's Debt to Equity history spans 4 years, with the latest figure at $0.12 for Q3 2025.
- For Q3 2025, Debt to Equity fell 40.77% year-over-year to $0.12; the TTM value through Sep 2025 reached $0.12, down 40.77%, while the annual FY2024 figure was $0.25, 12.47% up from the prior year.
- Debt to Equity for Q3 2025 was $0.12 at Cue Biopharma, down from $0.14 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.51 in Q1 2025 and bottomed at $0.12 in Q3 2025.
- The 4-year median for Debt to Equity is $0.21 (2024), against an average of $0.22.
- The largest YoY upside for Debt to Equity was 113.72% in 2025 against a maximum downside of 50.34% in 2025.
- A 4-year view of Debt to Equity shows it stood at $0.15 in 2022, then skyrocketed by 44.64% to $0.22 in 2023, then rose by 12.47% to $0.25 in 2024, then tumbled by 49.75% to $0.12 in 2025.
- Per Business Quant, the three most recent readings for CUE's Debt to Equity are $0.12 (Q3 2025), $0.14 (Q2 2025), and $0.51 (Q1 2025).